Literature DB >> 10349502

IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease.

H Bessler1, R Djaldetti, H Salman, M Bergman, M Djaldetti.   

Abstract

The capacity of peripheral blood mononuclear cells (PBMC) from patients with treated Parkinson's disease (PD) to produce interleukin (IL) IL-1 beta IL-2, IL-6, tumor necrosis factor (TNF)-alpha and the proliferative response to mitogens, was compared with that from cells from healthy subjects. The production of IL-2 and the mitogen response were significantly lower in PD patients, whereas the secretion of IL-1 beta, IL-6 and TNF-alpha were significantly enhanced. To evaluate the role of levodopa in creating immunological alterations, PBMC of patients and controls were incubated with concentrations of the drug extrapolated from those used in clinical practice. Levodopa caused an inhibition of mitogen-induced proliferation, stimulation of IL-6 and TNF-alpha production, whereas the secretion of IL-1 beta and IL-2 was not affected. The results of the study provide a further support for the interrelationship between the central nervous and immune system. In addition, the data indicate that the immunological alterations found in PD may be partially attributed to levodopa administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349502     DOI: 10.1016/S0753-3322(99)80079-1

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  46 in total

1.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 2.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

Authors:  Silvia Mandel; Edna Grünblatt; Gila Maor; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 4.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

5.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

6.  Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.

Authors:  Sonal Agrawal; Ashish Singh; Pratibha Tripathi; Manisha Mishra; Pradhyumna Kumar Singh; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-04-24       Impact factor: 5.590

Review 7.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

8.  Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons.

Authors:  Ping He; Qiang Liu; Jie Wu; Yong Shen
Journal:  FASEB J       Date:  2011-10-07       Impact factor: 5.191

Review 9.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

10.  Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

Authors:  Minho Moon; Hyo Geun Kim; Lakkyong Hwang; Ji-Hyung Seo; Sehee Kim; Sunyoung Hwang; Soonyong Kim; Dahm Lee; Hyunju Chung; Myung Sook Oh; Kyung-Tae Lee; Seungjoon Park
Journal:  Neurotox Res       Date:  2009-03-17       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.